HK1201740A1 - APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS - Google Patents

APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS Download PDF

Info

Publication number
HK1201740A1
HK1201740A1 HK15102316.6A HK15102316A HK1201740A1 HK 1201740 A1 HK1201740 A1 HK 1201740A1 HK 15102316 A HK15102316 A HK 15102316A HK 1201740 A1 HK1201740 A1 HK 1201740A1
Authority
HK
Hong Kong
Prior art keywords
ngf
aptamer
seq
aptamers
sequence
Prior art date
Application number
HK15102316.6A
Other languages
English (en)
Chinese (zh)
Inventor
．施奈德
D．J．施奈德
久美奈明彥
久美奈明彦
．沃
S.沃
．雷尼考
D．雷尼考
長嚢晃
长嚢晃
小野俊秀
Original Assignee
私募蛋白质体公司
大冢制药株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 私募蛋白质体公司, 大冢制药株式会社 filed Critical 私募蛋白质体公司
Publication of HK1201740A1 publication Critical patent/HK1201740A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK15102316.6A 2010-04-12 2015-03-06 APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS HK1201740A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32314510P 2010-04-12 2010-04-12
US61/323,145 2010-04-12

Publications (1)

Publication Number Publication Date
HK1201740A1 true HK1201740A1 (en) 2015-09-11

Family

ID=44798979

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102316.6A HK1201740A1 (en) 2010-04-12 2015-03-06 APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS

Country Status (24)

Country Link
US (7) US20110275794A1 (https=)
EP (3) EP3345915B1 (https=)
JP (4) JP5901610B2 (https=)
KR (4) KR20130043099A (https=)
CN (4) CN102985435B (https=)
AR (1) AR081452A1 (https=)
AU (2) AU2011240774B2 (https=)
BR (2) BR112012025872B8 (https=)
CA (3) CA2797188C (https=)
CO (1) CO6630139A2 (https=)
DK (1) DK2558478T3 (https=)
EA (1) EA022429B1 (https=)
ES (3) ES2610159T3 (https=)
HK (1) HK1201740A1 (https=)
IL (5) IL222339A (https=)
MX (4) MX392756B (https=)
MY (1) MY160608A (https=)
NO (1) NO2558478T3 (https=)
NZ (1) NZ602618A (https=)
PH (1) PH12012501838A1 (https=)
SG (3) SG184497A1 (https=)
TW (6) TWI505833B (https=)
UA (1) UA105290C2 (https=)
WO (2) WO2011130289A1 (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5993279A (ja) * 1982-11-17 1984-05-29 富士通株式会社 ロボツトによるカ−ド，レシ−ト分離取出し方法
US20110136099A1 (en) * 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8404830B2 (en) * 2007-07-17 2013-03-26 Somalogic, Inc. Method for generating aptamers with improved off-rates
EP3345915B1 (en) 2010-04-12 2021-11-24 Somalogic, Inc. 5-position modified pyrimidines and their use
WO2012061810A1 (en) * 2010-11-05 2012-05-10 Miragen Therapeutics Base modified oligonucleotides
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2868096C (en) 2012-03-28 2019-12-31 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
EP2836608A4 (en) * 2012-04-13 2016-02-24 Somalogic Inc TUBERCULOSIS BIOMARKERS AND USES THEREOF
KR101556339B1 (ko) 2012-07-02 2015-10-13 국립대학법인 울산과학기술대학교 산학협력단 페리오스틴에 대한 압타머 및 이를 포함하는 항암제 조성물
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
AU2013340414B2 (en) 2012-10-23 2019-05-02 Caris Science, Inc. Aptamers and uses thereof
EP2935628B1 (en) 2012-12-19 2018-03-21 Caris Life Sciences Switzerland Holdings GmbH Compositions and methods for aptamer screening
CA2902186C (en) * 2013-03-14 2023-04-11 Somalogic, Inc. Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
TWI594975B (zh) 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
WO2014177510A2 (en) * 2013-05-03 2014-11-06 Creabilis Sa Polymer conjugates of indolocarbazole compounds in the treatment of pruritus
GB201312295D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Suppression of itch
US9695424B2 (en) 2013-09-09 2017-07-04 Somalogic, Inc. PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
JP6506768B2 (ja) * 2013-09-24 2019-04-24 ソマロジック・インコーポレーテッド 多重アプタマー標的の検出
JP2015062365A (ja) * 2013-09-25 2015-04-09 Ｎｅｃソリューションイノベータ株式会社 ラクトパミンに結合する核酸分子およびその用途
JP2015062364A (ja) * 2013-09-25 2015-04-09 Ｎｅｃソリューションイノベータ株式会社 クレンブテロールに結合する核酸分子およびその用途
WO2015066001A1 (en) * 2013-10-29 2015-05-07 Albert Einstein College Of Medicine Of Yeshiva University Nucleic acid-scaffolded small molecule libraries
BR112016010165A2 (pt) * 2013-11-21 2017-12-05 Somalogic Inc composições de nucleotídeos modificados de citidina-5-carboxamida e métodos relacionados às mesmas
CA2943772C (en) * 2014-03-24 2022-07-19 Ribomic Inc. Aptamer for fgf2 and use thereof
NO2718257T3 (https=) * 2014-05-30 2018-04-14
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
CN104561013A (zh) * 2015-01-05 2015-04-29 中国人民解放军南京军区福州总医院 基于高通量测序技术进行核酸适配体序列优化的方法
ES2880766T3 (es) 2016-02-09 2021-11-25 Pharmakea Inc Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos
JP6853265B2 (ja) * 2016-03-14 2021-03-31 ソマロジック, インコーポレイテッドSomaLogic, Inc. 核酸に組み込むための５−（ｎ−保護−トリプタミノカルボキシアミド）−２’−デオキシウリジンホスホロアミダイトの化合物及び合成方法
CN107663220B (zh) * 2016-07-27 2020-10-02 上海伯豪医学检验所有限公司 修饰碱基、包含修饰碱基的核酸、适配体及其应用
CN110023499A (zh) 2016-10-24 2019-07-16 拜欧亿思有限公司 肿瘤坏死因子-α(TNF-α)结合适配体及其治疗用途
DK3548652T3 (da) 2016-12-01 2024-07-08 Nautilus Subsidiary Inc Fremgangsmåder til proteinanalyse
KR20250152680A (ko) 2017-12-29 2025-10-23 노틸러스 서브시디어리, 인크. 단백질 식별을 위한 디코딩 접근법
CN108299518A (zh) * 2018-02-02 2018-07-20 王成宇 一种2`-脱氧-β-尿苷的合成方法
EP3754021A4 (en) 2018-02-12 2021-11-10 Aptacure Therapeutics Limited SCLEROSTINE APTAMER AND ITS USE
EP3810563A4 (en) * 2018-06-22 2022-03-23 Somalogic, Inc. IMPROVED PROTEOMIC MULTIPLEX TESTS
WO2020198011A1 (en) 2019-03-22 2020-10-01 Somalogic, Inc. Reducing intersample analyte variability in complex biological matrices
SG11202111365QA (en) 2019-05-17 2021-11-29 Somalogic Inc Controlling intersample analyte variability in complex biological matrices
AU2021288692A1 (en) 2020-06-11 2023-02-02 Nautilus Subsidiary, Inc. Methods and systems for computational decoding of biological, chemical, and physical entities
EP4281774B1 (en) 2021-01-20 2025-11-26 Nautilus Subsidiary, Inc. Biomolecule quantitation
EP4281775B1 (en) 2021-01-21 2026-04-29 Nautilus Subsidiary, Inc. Systems and methods for biomolecule preparation
IL305336B2 (en) 2021-03-11 2025-09-01 Nautilus Subsidiary Inc Systems and methods for preserving biomolecules
EP4316495A4 (en) 2021-03-25 2025-12-31 Aptacure Therapeutics Ltd CONJUGATE OF NUCLEIC ACID MOLECULE HAVING A PROLONGED IN VIVO HALF-LIFE
CN113481204B (zh) * 2021-07-02 2022-08-12 湖南赛奥维生物技术有限公司 一种蛋白的核酸适配体、其衍生物及其应用
CA3227872A1 (en) 2021-09-09 2023-03-16 James Henry JOLY Characterization and localization of protein modifications
CA3227592A1 (en) 2021-09-22 2023-03-30 Gregory KAPP Methods and systems for determining polypeptide interactions
CN117916377A (zh) 2021-09-26 2024-04-19 安沛治疗有限公司 针对dkk1的适体及其用途
US20230149883A1 (en) 2021-11-03 2023-05-18 Nautilus Biotechnology, Inc. Systems and methods for surface structuring
US12092578B2 (en) 2022-03-29 2024-09-17 Nautilus Subsidiary, Inc. Integrated arrays for single-analyte processes
WO2023212490A1 (en) 2022-04-25 2023-11-02 Nautilus Subsidiary, Inc. Systems and methods for assessing and improving the quality of multiplex molecular assays
EP4544077A1 (en) 2022-06-21 2025-04-30 Nautilus Subsidiary, Inc. Method for detecting analytes at sites of optically non-resolvable distances
WO2024059655A1 (en) 2022-09-15 2024-03-21 Nautilus Subsidiary, Inc. Characterizing accessibility of macromolecule structures
WO2024073599A1 (en) 2022-09-29 2024-04-04 Nautilus Subsidiary, Inc. Preparation of array surfaces for single-analyte processes
WO2024107857A1 (en) 2022-11-15 2024-05-23 Nautilus Subsidiary, Inc. Standard polypeptides
WO2024124073A1 (en) 2022-12-09 2024-06-13 Nautilus Subsidiary, Inc. A method comprising performing on a single-analyte array at least 50 cycles of a process
US20240201182A1 (en) 2022-12-15 2024-06-20 Nautilus Subsidiary, Inc. Inhibition of photon phenomena on single molecule arrays
US20240241110A1 (en) 2023-01-12 2024-07-18 Nautilus Subsidiary, Inc. Characterization of glycans and glycoconjugates
EP4689173A1 (en) 2023-03-24 2026-02-11 Nautilus Subsidiary, Inc. Improved transfer of nanoparticles to array surfaces
WO2024216233A1 (en) 2023-04-13 2024-10-17 Nautilus Subsidiary, Inc. Artificial proteins for displaying epitopes
JPWO2024228396A1 (https=) * 2023-05-01 2024-11-07
US20240394902A1 (en) 2023-05-24 2024-11-28 Nautilus Subsidiary, Inc. Systems and methods for machine vision
US20250189519A1 (en) 2023-12-11 2025-06-12 Nautilus Subsidiary, Inc. Methods and compositions of particle-based arrays
WO2025137166A1 (en) 2023-12-20 2025-06-26 Nautilus Subsidiary, Inc. Fluidic devices for single-analyte assays
US20250298016A1 (en) 2024-03-22 2025-09-25 Nautilus Subsidiary, Inc. Plasmonic particle systems for single-analyte assays
WO2025212338A1 (en) 2024-04-01 2025-10-09 Nautilus Subsidiary, Inc. Nanostructures for modulation of analyte conformation
WO2026003215A1 (fr) 2024-06-27 2026-01-02 Commissariat A L'energie Atomique Et Aux Energies Alternatives Bases modifiées chimiquement avec un groupement clivable et méthodes de sélection d'acides nucléiques fonctionnels les comprenant
CN119792485B (zh) * 2025-03-17 2025-06-24 温州医科大学附属口腔医院 一种抑菌促修复水凝胶敷料及制备方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4594339A (en) 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US5599720A (en) 1982-08-27 1997-02-04 Multilyte Limited Measurement of analyte concentration
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4737453A (en) 1984-12-12 1988-04-12 Immunomedics, Inc. Sandwich immunoassay utilizing a separation specific binding substance
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4752566A (en) 1985-12-17 1988-06-21 Genetics Institute, Inc. Displacement polynucleotide method and reagent complex employing labeled probe polynucleotide
US5047519A (en) 1986-07-02 1991-09-10 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
US4997818A (en) 1987-09-21 1991-03-05 The University Hospital Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas
SE8802173D0 (sv) 1988-06-10 1988-06-10 Astra Ab Pyrimidine derivatives
KR920701230A (ko) * 1989-06-05 1992-08-11 원본미기재 엑소뉴클레아제-내성 올리고뉴클레오티드 및 그 제조방법
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
WO1991006629A1 (en) 1989-10-24 1991-05-16 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
HUT61566A (en) 1990-03-13 1993-01-28 Acic Canada Inc Process for producing 2,2'-o-cyclonucleosides, nucleosides and their analogous compounds
CA2079109A1 (en) 1990-03-29 1991-09-30 John A. Latham Oligonucleotide-transport agent disulfide conjugates
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5476766A (en) 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US6030776A (en) 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
CA2104698A1 (en) 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
AU1456092A (en) 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5428149A (en) 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
US5580972A (en) 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5719273A (en) 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
JP4899014B2 (ja) * 1995-06-02 2012-03-21 イーシー・テクノロジー・エルエルシー 求核試薬および一酸化炭素を用いるパラジウム触媒ヌクレオシド修飾方法
JPH11513887A (ja) 1995-10-27 1999-11-30 ランバーグ，エリオット，アール． 特定のヌクレオチド配列の検出方法および組成物
US5945527A (en) 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6020483A (en) 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
JP3485023B2 (ja) * 1999-05-20 2004-01-13 東亞合成株式会社 ヌクレオシド化合物
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
EP1964569A3 (en) * 2000-04-13 2009-07-22 Pharmasset, Inc. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
US20030148335A1 (en) 2001-10-10 2003-08-07 Li Shen Detecting targets by unique identifier nucleotide tags
AU2003217379A1 (en) 2002-02-15 2003-09-09 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
EP1489171B1 (en) 2002-03-19 2012-10-31 Fujitsu Limited Functional molecule and process for producing the same
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
CA2407825A1 (en) 2002-10-11 2004-04-11 Andrew J. Simmonds Trap-tagging: a novel method for the identification and purification of rna-protein complexes
US20040176282A1 (en) 2003-01-09 2004-09-09 Brian Dalby Cellular delivery and activation of polypeptide-nucleic acid complexes
JP4119976B2 (ja) * 2003-02-07 2008-07-16 国立大学法人群馬大学 ５位置換ピリミジンデオキシヌクレオチド誘導体、及びそれを用いた核酸の合成方法
WO2005024042A2 (en) 2003-09-04 2005-03-17 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
EP1584923A3 (en) 2004-04-07 2006-01-04 Roche Diagnostics GmbH Stabilization of biomolecules in samples
US7674778B2 (en) 2004-04-30 2010-03-09 Alnylam Pharmaceuticals Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
JP2006117542A (ja) 2004-10-19 2006-05-11 Pias Arise Kk 神経成長因子産生抑制剤、並びにその神経成長因子産生抑制剤を配合した皮膚外用剤、化粧料、医薬部外品、痒み予防及び治療剤、及びアトピー性皮膚炎治療剤
EP1828217A2 (en) 2004-12-16 2007-09-05 Febit Biotech GmbH Polymerase-independent analysis of the sequence of polynucleotides
WO2007044427A2 (en) 2005-10-05 2007-04-19 Panomics, Inc. Detection of nucleic acids from whole blood
JP5256578B2 (ja) * 2005-12-20 2013-08-07 大正製薬株式会社 掻痒性皮膚疾患の予防または治療剤
WO2007084886A2 (en) 2006-01-17 2007-07-26 Somalogic, Incorporated Multiplexed analyses of test samples
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EP1897886A1 (en) * 2006-09-08 2008-03-12 Bayer Schering Pharma Aktiengesellschaft Compounds as aptamer-dimers and their uses in diagnosis and therapy
US8242258B2 (en) * 2006-12-03 2012-08-14 Agilent Technologies, Inc. Protecting groups for RNA synthesis
WO2008078180A2 (en) 2006-12-22 2008-07-03 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
EP2144921A2 (en) * 2007-02-27 2010-01-20 K.U. Leuven Research and Development Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
EP2152870A2 (en) * 2007-05-02 2010-02-17 Sirna Therapeutics Inc. Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina)
US8404830B2 (en) 2007-07-17 2013-03-26 Somalogic, Inc. Method for generating aptamers with improved off-rates
DK2172566T4 (da) * 2007-07-17 2022-06-13 Somalogic Inc Fremgangsmåde til generering af aptamerer med forbedrede off-rates
US20090215050A1 (en) 2008-02-22 2009-08-27 Robert Delmar Jenison Systems and methods for point-of-care amplification and detection of polynucleotides
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
ES2543222T3 (es) 2008-09-24 2015-08-17 Ribomic Inc. Aptámero para NGF y uso del mismo
CA2808233C (en) 2010-03-03 2017-07-11 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
CA2794199C (en) 2010-03-24 2017-11-14 Shionogi & Co., Ltd. Aptamer for ngf and use thereof
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
WO2011130065A1 (en) 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP3345915B1 (en) 2010-04-12 2021-11-24 Somalogic, Inc. 5-position modified pyrimidines and their use
WO2012061810A1 (en) * 2010-11-05 2012-05-10 Miragen Therapeutics Base modified oligonucleotides
CA2868096C (en) * 2012-03-28 2019-12-31 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
BR112016010165A2 (pt) 2013-11-21 2017-12-05 Somalogic Inc composições de nucleotídeos modificados de citidina-5-carboxamida e métodos relacionados às mesmas

Also Published As

Publication number Publication date
KR102185779B1 (ko) 2020-12-03
NZ602618A (en) 2013-12-20
EP2558586B1 (en) 2016-10-12
US20140058076A1 (en) 2014-02-27
CN102858990B (zh) 2016-08-03
BR122021003805B1 (pt) 2021-10-13
KR20130103317A (ko) 2013-09-23
KR20190018750A (ko) 2019-02-25
MY160608A (en) 2017-03-15
SG184497A1 (en) 2012-11-29
TW201730198A (zh) 2017-09-01
ES2667491T3 (es) 2018-05-11
AU2011240677B2 (en) 2015-05-14
TW201900668A (zh) 2019-01-01
MX2020003168A (es) 2022-05-31
CN102985435A (zh) 2013-03-20
CA2797188C (en) 2020-03-31
JP6352324B2 (ja) 2018-07-04
US20130012693A1 (en) 2013-01-10
BR112012025872B8 (pt) 2021-05-25
CN102858990A (zh) 2013-01-02
BR112012025872B1 (pt) 2021-04-20
KR101842269B1 (ko) 2018-03-26
DK2558478T3 (en) 2018-05-22
TWI684596B (zh) 2020-02-11
KR20180030229A (ko) 2018-03-21
EA201291034A1 (ru) 2013-04-30
TWI505833B (zh) 2015-11-01
IL256014A (en) 2018-01-31
CO6630139A2 (es) 2013-03-01
JP6012591B2 (ja) 2016-10-26
IL222339A0 (en) 2012-12-31
ES2905656T3 (es) 2022-04-11
US10221207B2 (en) 2019-03-05
AU2011240677A1 (en) 2012-11-01
EP2558478A1 (en) 2013-02-20
PH12012501838A1 (en) 2013-02-04
KR20130043099A (ko) 2013-04-29
CA3066785A1 (en) 2011-10-20
JP2013523177A (ja) 2013-06-17
CA2793451A1 (en) 2011-10-20
EA022429B1 (ru) 2015-12-30
EP2558586A4 (en) 2014-10-15
EP2558478A4 (en) 2013-10-23
BR122021003805B8 (pt) 2022-10-25
US20190233461A1 (en) 2019-08-01
JP2013523887A (ja) 2013-06-17
CN107033204A (zh) 2017-08-11
KR101952671B1 (ko) 2019-02-27
IL222339A (en) 2015-11-30
TWI593701B (zh) 2017-08-01
US20110275794A1 (en) 2011-11-10
BR112012025872A2 (pt) 2016-10-18
IL242038A0 (en) 2015-11-30
MX2012011779A (es) 2012-12-17
MX392756B (es) 2025-03-24
EP2558586A1 (en) 2013-02-20
CN104069512A (zh) 2014-10-01
HK1252803A1 (en) 2019-06-06
UA105290C2 (ru) 2014-04-25
IL256014B (en) 2018-05-31
TW201629079A (zh) 2016-08-16
IL256013B (en) 2018-05-31
US8598140B2 (en) 2013-12-03
CN102985435B (zh) 2016-10-26
TWI671309B (zh) 2019-09-11
JP7025818B2 (ja) 2022-02-25
IL252703A0 (en) 2017-08-31
US20160355540A1 (en) 2016-12-08
AR081452A1 (es) 2012-09-05
SG184089A1 (en) 2012-11-29
US9163056B2 (en) 2015-10-20
WO2011130289A1 (en) 2011-10-20
JP2016145230A (ja) 2016-08-12
TW201936623A (zh) 2019-09-16
EP3345915B1 (en) 2021-11-24
TW201134482A (en) 2011-10-16
WO2011130195A1 (en) 2011-10-20
EP3345915A1 (en) 2018-07-11
IL252703A (en) 2017-12-31
MX2012011771A (es) 2012-12-17
TW202019943A (zh) 2020-06-01
TWI643864B (zh) 2018-12-11
AU2011240774A1 (en) 2012-10-18
IL242038A (en) 2017-07-31
CA2797188A1 (en) 2011-10-20
AU2011240774B2 (en) 2014-04-10
EP2558478B1 (en) 2018-03-07
JP2018109050A (ja) 2018-07-12
IL256013A (en) 2018-01-31
NO2558478T3 (https=) 2018-08-04
MX373860B (es) 2020-03-25
ES2610159T3 (es) 2017-04-26
SG2014006522A (en) 2014-03-28
US20150376223A1 (en) 2015-12-31
JP5901610B2 (ja) 2016-04-13
US20180127450A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
CN102858990B (zh) 针对β-NGF的适体及其在治疗β-NGF介导的疾病和失调中的用途
KR101802540B1 (ko) Ｆｌｇ의 발현 및 활성을 조절함으로써 필라그린(ｆｌｇ)에 관련된 질환의 치료
AU2011223527B2 (en) Aptamers to 4-1BB and their use in treating diseases and disorders
KR102242874B1 (ko) Ｉｌ―６에 결합하는 압타머 및 ｉｌ―６ 매개된 질환을 치료하거나 진단하는 데에서 이의 용도
CN115087452A (zh) 用于治疗病况和疾病的反义寡聚体
CN113490739A (zh) 通过磷酸二酯酶4(pde4)抑制治疗癫痫的方法
KR20250155076A (ko) 안티센스 올리고머 제형
EP2897633B1 (en) Treatment of pain by inhibition of usp5 de-ubiquitinase
HK1180368A (en) APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS
Boules et al. Down-regulation of amyloid precursor protein by peptide nucleic acid in vivo
ES2664179T3 (es) Compuestos de ácido nucleico para unión a una proteína de componente 3 del complemento
TW201336860A (zh) 針對ａｃｓｌ１之反意寡核苷酸
TW202604552A (zh) 用於降低atxn3表達之修飾寡核苷酸
KR20260055532A (ko) 병태 및 질환 치료 방법
WO2025252669A1 (en) Modified oligonucleotides for reducing atxn3 expression
CN121969747A (zh) 用于治疗疾患和疾病的方法
JPWO1998039438A1 (ja) Ｃｄ１４に対するアンチセンス化合物
HK1217512B (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions